Our findings indicate that KLF5 is highly associated with poor overall survival of patients with lung adenocarcinoma, suggesting that targeting KLF5-driven malignancy may provide an opportunity for developing lung cancer therapeutics (Figure 6F). Here, KLF5 is linked to lung carcinoma.